Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury

PHASE3CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

November 30, 2003

Study Completion Date

February 29, 2004

Conditions
Spinal Cord InjuryMuscle Spasticity
Interventions
DRUG

Fampridine-SR

25mg bid (twice daily)

DRUG

Placebo

Placebo

Trial Locations (30)

13045

SUNY Upstate Clinical Trials Office, Syracuse

Helen Hayes Hospital, West Haverstraw

14642

University of Rochester/Strong Memorial Hospital, Rochester

19107

Thomas Jefferson University Hospital, Philadelphia

22042

INOVA Institute of Research and Education, Falls Church

23298

Medical College of Virginia/VCU, Richmond

28203

Charlotte Institute of Rehabilitation, Charlotte

28402

Coastal AHEC, Wilmington

35233

UAB School of Medicine, 190 Spain Rehab Center, Birmingham

43210

Ohio State University, Columbus

45409

Miami Valley Hospital- Rehabilitation Institute of Medicine, Dayton

48109

University of Michigan, Ann Arbor

48201

Rehabilitation Institute of Michigan, Detroit

53295

Wood VA Medical Center, Milwaukee

55417

Minneapolis VA Hospital, Minneapolis

60141

Hines VA Hospital, Hines

63104

St. Louis University, St Louis

65212

University of Missouri, Columbia

75216

VA North Texas Health Care System, Dallas

75390

Southwestern Medical Center at Dallas, Dallas

80110

Craig Hospital, Englewood

90822

Long Beach VA Medical Center, Long Beach

95128

Santa Clara Valley Medical Center, San Jose

95817

University of California, Davis, Sacramento

98195

University of Washington Medical Center, Dept. of Rehabilitation, Seattle

06503

Hospital for Special Care, New Britain

02118

Boston University Medical Center, Boston

R3A 1M4

Health Sciences Centre, Winnipeg

L8N 3Z5

Chedoke-McMaster Hospital, Hamilton

K7L 5A2

St. Mary's of the Lake Hospital, Kingston

Sponsors
All Listed Sponsors
lead

Acorda Therapeutics

INDUSTRY